release cisplatin combined with radiation for the treatment of canine nasal tumors. Vet Radiol Ultrasound 38:474–478.369 Lana, S., L. U'ren, S. Plaza, et al. 2007. Continuous low‐dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med 21:764–769.
370 Lane, A., M. Black, and K. Wyatt. 2012. Toxicity and efficacy of a novel doxorubicin and carboplatin chemotherapy protocol for the treatment of canine appendicular osteosarcoma following limb amputation. Aust Vet J 90:69–74.
371 Langer, S.W., A.V. Thougaard, M. Sehested, et al. 2006. Treatment of anthracycline extravasation in mice with dexrazoxane with or without Dmso and hydrocortisone. Cancer Chemother Pharmacol 57:125–128.
372 Langova, V., A.J. Mutsaers, B. Phillips, et al. 2004. Treatment of eight dogs with nasal tumours with alternating doses of doxorubicin and carboplatin in conjunction with oral piroxicam. Aust Vet J 82:676–680.
373 Larue, S.M. and I.K. Gordon. 2013. 12 – Radiation therapy. In Withrow and MacEwen's Small Animal Clinical Oncology, 5th edition. R.L. Page, S.J. Withrow, and D.M. Vail, editors. St. Louis: W.B. Saunders.
374 Larue, S.M., S.J. Withrow, B.E. Powers, et al. 1989. Limb‐sparing treatment for osteosarcoma in dogs. J Am Vet Med Assoc 195:1734–1744.
375 Lascelles, B.D., R.A. Henderson, B. Seguin, et al. 2004. Bilateral rostral maxillectomy and nasal planectomy for large rostral maxillofacial neoplasms in six dogs and one cat. J Am Anim Hosp Assoc 40:137–146.
376 Lascelles, B.D., M.J. Thomson, W.S. Dernell, et al. 2003. Combined dorsolateral and intraoral approach for the resection of tumors of the maxilla in the dog. J Am Anim Hosp Assoc 39:294–305.
377 Lavalle, G.E., C.B. De Campos, A.C. Bertagnolli, et al. 2012. Canine malignant mammary gland neoplasms with advanced clinical staging treated with carboplatin and cyclooxygenase inhibitors. in vivo 26:375–379.
378 Laver, T., B.R. Feldhaeusser, C.S. Robat, et al. 2018a. Post‐surgical outcome and prognostic factors in canine malignant melanomas of the haired skin: 87 cases (2003–2015). Can Vet J 59(9):981–987.
379 Laver, T., C.A. London, D.M. Vail, et al. 2018b. Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma. Vet Comp Oncol 16(1):E23–E29.
380 Lawrence, J.A., L.J. Forrest, M.M. Turek, et al. 2010. Proof of principle of ocular sparing in dogs with sinonasal tumors treated with intensity‐modulated radiation therapy. Vet Radiol Ultrasound 51:561–570.
381 Leach, T.N., M.O. Childress, S.N. Greene, et al. 2012. Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer. Vet Comp Oncol 10:102–112.
382 Leav, I., A.L. Schiller, A. Rijnberk, et al. 1976. Adenomas and carcinomas of the canine and feline thyroid. Am J Pathol 83:61–122.
383 Lecuyer, M., S. Prini, M.E. Dunn, et al. 2006. Clinical efficacy and safety of transdermal methimazole in the treatment of feline hyperthyroidism. Can Vet J 47:131–135.
384 Lee, H.C., J.H. Kim, C.H. Jee, et al. 2014. A case of gastric adenocarcinoma in a Shih Tzu dog: Successful treatment of early gastric cancer. J Vet Med Sci 76:1033–1038.
385 Leifer, C.E., M.E. Peterson, and R.E. Matus. 1986. Insulin‐secreting tumor: Diagnosis and medical and surgical management in 55 dogs. J Am Vet Med Assoc 188:60–64.
386 Lejeune, A., K. Skorupski, S. Frazier, et al. 2015. Aggressive local therapy combined with systemic chemotherapy provides long‐term control in grade II stage 2 canine mast cell tumour: 21 cases (1999–2012). Vet Comp Oncol 13:267–280.
387 Lengerich, E.J., R.F. Teclaw, J.M. Mendlein, et al. 1992. Pet populations in the catchment area of the Purdue Comparative Oncology Program. J Am Vet Med Assoc 200:51–56.
388 L’Eplattenier H.F., B. Klem, E. Teske, et al. 2008. Preliminary results of intraoperative photodynamic therapy with 5‐aminolevulinic acid in dogs with prostate carcinoma. Vet J 178:202–207.
389 L’Eplattenier, H.F., S.A. Van Nimwegen, F.J. Van Sluijs, et al. 2006. Partial prostatectomy using Nd:Yag laser for management of canine prostate carcinoma. Vet Surg 35:406–411.
390 Liao, A.T., M.B. Chien, N. Shenoy, et al. 2002. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 100:585–593.
391 Lidbetter, D.A., F.A. WilliamsJr., D.J. Krahwinkel, et al. 2002. Radical lateral body‐wall resection for fibrosarcoma with reconstruction using polypropylene mesh and a caudal superficial epigastric axial pattern flap: A prospective clinical study of the technique and results in 6 cats. Vet Surg 31:57–64.
392 Liptak, J.M. and N.S. Brebner. 2006. Hemidiaphragmatic reconstruction with a transversus abdominis muscle flap after resection of a solitary diaphragmatic mesothelioma in a dog. J Am Vet Med Assoc 228:1204–1208.
393 Liptak, J.M., S.P. Brutscher, E. Monnet, et al. 2004a. Transurethral resection in the management of urethral and prostatic neoplasia in 6 dogs. Vet Surg 33:505–516.
394 Liptak, J.M., W.S. Dernell, N. Ehrhart, et al. 2006. Cortical allograft and endoprosthesis for limb‐sparing surgery in dogs with distal radial osteosarcoma: A prospective clinical comparison of two different limb‐sparing techniques. Vet Surg 35:518–533.
395 Liptak, J.M., W.S. Dernell, B.D. Lascelles, et al. 2004b. Intraoperative extracorporeal irradiation for limb sparing in 13 dogs. Vet Surg 33:446–456.
396 Liptak, J.M. and L.J. Forrest. 2013. 21 – soft tissue sarcomas. In Withrow and MacEwen's Small Animal Clinical Oncology, 5th edition. R.L. Page, S.J. Withrow, and D.M. Vail, editors. St. Louis: W.B. Saunders.
397 Liptak, J.M., G.E. Pluhar, W.S. Dernell, et al. 2005. Limb‐sparing surgery in a dog with osteosarcoma of the proximal femur. Vet Surg 34:71–77.
398 Little, C.J., G.R. Pearson, and J.G. Lane. 1989. Neoplasia involving the middle ear cavity of dogs. Vet Rec 124:54–57.
399 Lombardi, P., S. Florio, U. Pagnini, et al. 1999. Ovarian function suppression with a GnRH analogue: D‐ser(But[t])[6]‐Arzgly[10]‐Lhrh (Goserelin) in hormone dependent canine mammary cancer. J Vet Pharmacol Ther 22:56–61.
400 London, C.A., R.R. Dubilzeig, D.M. Vail, et al. 1996. Evaluation of dogs and cats with tumors of the ear canal: 145 cases (1978–1992). J Am Vet Med Assoc 208:1413–1418.
401 London, C.A., H.L. Gardner, T. Mathie, et al. 2015. Impact of toceranib/piroxicam/cyclophosphamide maintenance therapy on outcome of dogs with appendicular osteosarcoma following amputation and carboplatin chemotherapy: A multi‐institutional study. PLoS One 10:e0124889.
402 London, C.A., A.L. Hannah, R. Zadovoskaya, et al. 2003. Phase I dose‐escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 9:2755–2768.
403 London, C.A., P.B. Malpas, S.L. Wood‐Follis, et al. 2009. Multi‐center, placebo‐controlled, double‐blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 15:3856–3865.
404 London, C., T.Mathie, N.Stingle et al. 2012. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours. Vet Comp Oncol 10(3):194–205.
